CRISPR Therapeutics AG

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 1.19%137.880.0%$904.62m
AMGNAmgen, Inc. 1.04%250.081.5%$837.59m
GILDGilead Sciences, Inc. 0.49%64.151.0%$544.64m
VRTXVertex Pharmaceuticals, Inc. 4.32%269.761.9%$481.90m
REGNRegeneron Pharmaceuticals, Inc. 3.67%685.422.6%$437.60m
ILMNIllumina, Inc. 0.82%245.483.3%$316.36m
NVAXNovavax, Inc. -1.27%52.7475.7%$303.59m
BIIBBiogen, Inc. 0.49%200.631.8%$241.23m
BNTXBioNTech SE 0.30%163.490.0%$227.09m
SNSSSunesis Pharmaceuticals, Inc. -0.47%2.100.7%$146.80m
EXASEXACT Sciences Corp. -2.13%52.0417.7%$143.96m
NKTXNkarta, Inc. 0.71%12.760.0%$99.97m
TECHBio-Techne Corp. -0.98%362.754.5%$99.81m
BMRNBioMarin Pharmaceutical, Inc. 1.29%80.754.2%$99.68m
TXG10X Genomics, Inc. -1.75%49.280.0%$99.51m

Company Profile

CRISPR Therapeutics AG is a gene editing company, which is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.